NEWS - May 8, 2023 Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023 Read more
NEWS - Mar 23, 2023 Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results Read more
NEWS - Mar 17, 2023 Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023 Read more
NEWS - Jan 12, 2023 Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors Read more
NEWS - Jan 9, 2023 Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer Read more
NEWS - Dec 7, 2022 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder Read more
NEWS - Nov 10, 2022 Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results Read more
NEWS - Nov 8, 2022 Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022 Read more
NEWS - Oct 13, 2022 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder Read more
NEWS - Sep 20, 2022 Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder Read more
